Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Evans

Showing results (21-30 of 154) with videos related to

Pageof 16
Sort By:
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 4, 2020
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome StudiesDavid M Williams, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 27, 2017
Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UKMarc Evans, Sayeed Achha, Cheryl Neslusan
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 18, 2017
Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes MellitusMarc Evans, Barrie Chubb, Jens Gundgaard
Current Opinion in Lipidology|November 21, 2002
The future direction of cholesterol-lowering therapyMarc Evans, Aled Roberts, Alan Rees
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 6, 2019
Fast-Acting Insulin Aspart: The Rationale for a New Mealtime InsulinMarc Evans, Mathew Wilkinson, Angeliki Giannpolou
Journal of Medical Economics|October 18, 2014
Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluationMarc Evans, Phil McEwan, Volker Foos
Vascular Health and Risk Management|August 31, 2016
Blood pressure and fasting lipid changes after 24 weeks' treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitusMarc Evans, Anja Schweizer, James E Foley
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 13, 2020
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome TrialsDavid M Williams, Asif Nawaz, Marc Evans
Stroke|March 2, 2023
Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?David M Williams, Michael Atkinson, Marc Evans
Expert Review of Endocrinology & Metabolism|July 31, 2018
A systematic review of the safety of incretin-based therapies in type 2 diabetesMarc Evans, Stephen C Bain, Jiten Vora
Pageof 16

Showing results (21-30 of 154) with videos related to

Sort By:
Pageof 16
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 4, 2020
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome StudiesDavid M Williams, Marc Evans
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 27, 2017
Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UKMarc Evans, Sayeed Achha, Cheryl Neslusan
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 18, 2017
Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes MellitusMarc Evans, Barrie Chubb, Jens Gundgaard
Current Opinion in Lipidology|November 21, 2002
The future direction of cholesterol-lowering therapyMarc Evans, Aled Roberts, Alan Rees
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 6, 2019
Fast-Acting Insulin Aspart: The Rationale for a New Mealtime InsulinMarc Evans, Mathew Wilkinson, Angeliki Giannpolou
Journal of Medical Economics|October 18, 2014
Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice--a case-based evaluationMarc Evans, Phil McEwan, Volker Foos
Vascular Health and Risk Management|August 31, 2016
Blood pressure and fasting lipid changes after 24 weeks' treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitusMarc Evans, Anja Schweizer, James E Foley
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|November 13, 2020
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome TrialsDavid M Williams, Asif Nawaz, Marc Evans
Stroke|March 2, 2023
Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?David M Williams, Michael Atkinson, Marc Evans
Expert Review of Endocrinology & Metabolism|July 31, 2018
A systematic review of the safety of incretin-based therapies in type 2 diabetesMarc Evans, Stephen C Bain, Jiten Vora
Pageof 16